相关实验视频
Updated: May 22, 2025

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.2K
慢性esaxerenone治疗改善了血管功能,并降低了患有异常性过高阿尔多斯特症的患者的外周动脉硬性
Shinji Kishimoto1, Tatsuya Maruhashi1, Masato Kajikawa2
1Department of Regenerative Medicine, Division of Radiation Medical Science, Research Institute for Radiation Biology and Medicine, Hiroshima University.
Journal of hypertension
|May 21, 2025
概括
埃萨克塞伦在患有异常性阿尔多多斯特症 (IHA) 的患者中改善了血管功能和动脉硬性. 这表明阿尔多素抑制可能会改善心血管健康.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 主要的阿尔多斯特主义是二次内分泌高血压的常见原因.
- 推使用矿物甲类皮质体受体对抗剂治疗双边异常性阿尔多多斯特隆症 (IHA).
研究的目的:
- 评估esaxerenone的作用,选择性的非类固醇矿物质皮质体受体对抗剂,在IHA患者的血管功能和外围动脉硬性.
主要方法:
- 一个单一中心的观察前性队列研究,涉及44名IHA患者.
- 测量包括流量介导血管扩张 (FMD),甘氨酸诱导血管扩张 (NID),臂脉冲波速度 (baPWV) 和臂动脉内心介质厚度 (bIMT) 在12周esaxerenone治疗前后.
主要成果:
- 埃萨克塞伦显著增加了口病和NID (P < 0.01).
- 埃萨克塞伦显著降低了baPWV (P < 0.01),但没有改变bIMT.
- 血管功能和硬度的变化与血中阿尔多素度 (PAC) 和血雷宁活性 (PRA) 的变化相关.
结论:
- 在IHA患者中,esaxerenone有效地改善了血管功能,并减少了外周动脉硬性.
- 这些结果表明,esaxerenone抑制阿尔多素可能是改善心血管健康的关键机制.
关键词:
这就是为什么ARR ARR.在 FMD 和 FMD 的情况下,哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈这些MRA是MRAs.矿物甲类皮质体受体对手的 NID NID 的 NID.这就是为什么PAC PAC PAC.这就是PRA的意义.阿尔多斯与雷宁的比率在此之前,BIMTTbaPWVV 在线观看臂动脉内心介质厚度 臂动脉内心介质厚度腕脉冲 波速 波速 波速 波速在 eNOS eNOS 中使用.脑内皮的内皮功能.体内氧化合成酶的作用.这样就没有一个人了.通过流体介导的血管扩张.异形性超阿尔多斯特主义 (idiopathic hyperaldosteronism) 是一种异形性超阿尔多斯特主义.亚甘油诱导的血管扩张.血中阿尔多斯特的度是多少血雷宁活性等离子体内.主要的阿尔多斯顿主义.相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Antihypertensive Drugs: Direct Renin Inhibitors
466
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
Heart Failure Drugs: Diuretics
312
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
312
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
436
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
436
Antihypertensive Drugs: Angiotensin II Receptor Blockers
561
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
561
Antihypertensive Drugs: Potassium-Sparing Diuretics
426
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
426

